Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

PHARMACEUTICAL ECONSULTING A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   6.6% 2.9% 1.8% 2.6% 6.6% 4.4% 10.8% 10.6%   Credit score (0-100)   37 58 71 61 35 47 23 23   Credit rating   BBB BBB A BBB BBB BBB BB BB   Credit limit (kDKK)   0.0 0.0 6.5 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   5,316 6,947 8,276 6,779 5,579 5,538 0.0 0.0   EBITDA   1,855 3,037 3,110 846 -313 -805 0.0 0.0   EBIT   1,523 2,978 3,050 770 -395 -941 0.0 0.0   Pre-tax profit (PTP)   1,557.1 3,015.5 3,107.8 1,007.1 -303.4 -892.0 0.0 0.0   Net earnings   1,210.6 2,345.1 2,419.8 779.6 -383.6 -643.9 0.0 0.0   Pre-tax profit without non-rec. items   1,557 3,015 3,108 1,007 -303 -892 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Tangible assets total   76.4 41.2 161 125 43.7 1,079 0.0 0.0   Shareholders equity total   2,702 4,048 6,467 7,247 6,863 6,220 5,720 5,720   Interest-bearing liabilities   0.0 9,744 9,814 0.0 11.8 1,705 0.0 0.0   Balance sheet total (assets)   14,116 17,132 19,658 8,092 7,991 8,806 5,720 5,720   Net Debt   -138 8,338 6,989 -59.5 -351 1,189 -5,720 -5,720     See the entire balance sheet 1000.0 Volume  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   5,316 6,947 8,276 6,779 5,579 5,538 0.0 0.0   Gross profit growth   38.0% 30.7% 19.1% -18.1% -17.7% -0.7% -100.0% 0.0%   Employees   4 4 5 8 8 8 0 0   Employee growth %   0.0% 0.0% 25.0% 60.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   14,116 17,132 19,658 8,092 7,991 8,806 5,720 5,720   Balance sheet change%   23.3% 21.4% 14.7% -58.8% -1.3% 10.2% -35.1% 0.0%   Added value   1,855.0 3,036.8 3,110.3 846.1 -318.9 -804.8 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -647 -94 60 -112 -163 899 -1,079 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 -1.0 -2.0 0.0 0.0   1000.0 Profitability  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   28.6% 42.9% 36.9% 11.4% -7.1% -17.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   13.7% 20.8% 18.2% 9.0% -3.3% -9.7% 0.0% 0.0%   ROI %   26.7% 39.4% 22.3% 10.6% -3.8% -11.0% 0.0% 0.0%   ROE %   46.6% 69.5% 46.0% 11.4% -5.4% -9.8% 0.0% 0.0%   1000.0 Solidity  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Equity ratio %   19.1% 23.6% 32.9% 89.6% 85.9% 70.6% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -7.4% 274.5% 224.7% -7.0% 112.1% -147.7% 0.0% 0.0%   Gearing %   0.0% 240.7% 151.7% 0.0% 0.2% 27.4% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   4.9% 4.8% 2.5% 4.9% 583.2% 9.3% 0.0% 0.0%   1000.0 Liquidity  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Quick Ratio   1.2 1.3 1.5 9.4 7.0 3.3 0.0 0.0   Current Ratio   1.2 1.3 1.5 9.4 7.0 3.3 0.0 0.0   Cash and cash equivalent   138.0 1,406.3 2,824.6 59.5 363.1 515.5 0.0 0.0   1000.0 Capital use efficiency  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   2,592.3 3,971.8 6,284.5 7,099.3 6,796.5 5,373.0 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   464 759 622 106 -40 -101 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   464 759 622 106 -39 -101 0 0   EBIT / employee   381 744 610 96 -49 -118 0 0   Net earnings / employee   303 586 484 97 -48 -80 0 0